BPR1K871
BPR1K871 is a potent and selective dual FLT3/AURKA inhibitor with IC50s of 19 nM and 22 nM for FLT3 and AURKA, respectively, acts as a preclinical development candidate for anti-cancer therapy[1].
Product Specifications
CAS Number
[2443767-35-7]
Product Name Alternative
DBPR114
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
FLT3
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bpr1k871.html
Purity
99.12
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC(Cl)=CC=C1)NC2=NC=C(S2)CCNC3=NC=NC4=C3C=CC(OCCCN(C)C)=C4
Molecular Formula
C25H28ClN7O2S
Molecular Weight
526.05
Precautions
H302, H315, H319, H335
References & Citations
[1]Hsu YC, et al. Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation. 2016 Dec 27; 7 (52) : 86239–86256.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
DMAB-CS23029 100 μg, 500 μg
Mouse Anti-N. gonorrhoeae Monoclonal antibody, clone 462.5
Ask
View Details 